勃起功能障礙藥物市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

2024 年全球勃起功能障礙藥物市場價值為 29 億美元，預計將實現強勁成長，預計 2025 年至 2034 年的複合年成長率為 9.2%。這些藥物的主要作用是增強陰莖區域的血流量，從而實現對性喚起的自然勃起。

市場分為西地那非枸櫞酸鹽、他達拉非、伐地那非、阿伐那非、烏地那非和其他配方。其中，枸櫞酸西地那非在 2024 年佔據主導地位，創造了 15 億美元的收入。其領先地位歸功於：

• 強大的品牌認知度
• 臨床療效已證實
• 廣泛用於治療 ED 的第一線藥物

快速起效、完善的安全性以及醫療保健提供者的持續偏好等其他優勢繼續鞏固其主導地位。人們對 ED 治療的認知不斷提高和全球人口老化，再加上糖尿病、肥胖症和心血管疾病的盛行率不斷上升，預計將在未來幾年進一步推動對西地那非枸櫞酸鹽的需求。

市場也根據給藥途徑分類，包括口服、腸胃外和其他方法。口服藥物成為 2024 年最受歡迎的選擇，佔了高達 83.2% 的市場。他們的主導地位得益於：

• 方便易用
• 廣泛適用，無需專業醫療監督
• 與門診護理高度相容

口服 ED 藥物可以謹慎的自我治療，與注射或其他給藥方式相比，可以提高患者的依從性和舒適度。

美國勃起功能障礙藥物市場預計將大幅成長，預計到 2034 年將達到 26 億美元。線上諮詢、訂閱服務和謹慎的送貨上門服務正在消除障礙、提高治療依從性並減少尋求 ED 解決方案時常常產生的恥辱感。

目錄

第 1 章：方法論與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 勃起功能障礙盛行率不斷上升
    • 藥物輸送系統的技術進步
    • 老齡人口不斷增加
  • 產業陷阱與挑戰
    • 副作用和安全問題
    • 嚴格的監管環境
• 成長潛力分析
• 監管格局
• 差距分析
• 管道分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第 5 章：市場估計與預測：按藥物，2021 年至 2034 年

• 主要趨勢
• 威而鋼（枸櫞酸西地那非）
• 希愛力（他達拉非）
• Levitra/Staxyn（伐地那非）
• Stendra/Spedra（阿伐那非）
• Zydena（烏地那非）
• 其他藥物

第 6 章：市場估計與預測：按管理路線，2021 年至 2034 年

• 主要趨勢
• 口服
• 腸外
• 其他給藥途徑

第 7 章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第9章：公司簡介

• Bayer
• Eli Lilly and Company
• Endo
• Futura Medical
• Hims & Hers Health
• Lupin
• Meda Pharmaceuticals
• Petros Pharmaceuticals
• Pfizer
• Sandoz
• Simple Pharma
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Zydus Lifesciences

The Global Erectile Dysfunction Drugs Market, valued at USD 2.9 billion in 2024, is on track to experience robust growth, with a projected CAGR of 9.2% from 2025 to 2034. ED medications are specifically designed to address the inability to achieve or sustain an erection sufficient for sexual satisfaction. These drugs work primarily by enhancing blood flow to the penile area, enabling natural erections in response to sexual arousal.

The market is segmented into Sildenafil Citrate, Tadalafil, Vardenafil, Avanafil, Udenafil, and other formulations. Among these, Sildenafil Citrate dominated in 2024, generating USD 1.5 billion in revenue. Its leading position is attributed to:

• Strong brand recognition
• Proven clinical efficacy
• Widespread use as a first-line treatment for ED

Additional advantages such as rapid onset, a well-established safety profile, and sustained preference among healthcare providers continue to solidify its dominance. Rising awareness of ED treatments and an aging global population, combined with the increasing prevalence of diabetes, obesity, and cardiovascular diseases, are expected to further drive demand for Sildenafil Citrate in the coming years.

The market is also classified by route of administration, including oral, parenteral, and other methods. Oral medications emerged as the most popular choice in 2024, capturing an impressive 83.2% of the market share. Their dominance is fueled by:

• Convenience and ease of use
• Wide availability without the need for specialized medical supervision
• High compatibility with outpatient care

Oral ED drugs allow for discreet, self-administered treatment, fostering better patient compliance and comfort compared to injections or alternative delivery methods.

The U.S. erectile dysfunction drugs market is poised for significant growth, projected to reach USD 2.6 billion by 2034. Key factors driving this expansion include the rapid adoption of telemedicine and digital health platforms, which have revolutionized access to ED treatments. Online consultations, subscription-based services, and discreet home delivery options are eliminating barriers, improving treatment adherence, and reducing the stigma often associated with seeking ED solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of erectile dysfunction
    • 3.2.1.2 Technological advancement in drug delivery systems
    • 3.2.1.3 Increasing aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and safety concerns
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Gap analysis
• 3.6 Pipeline analysis
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Viagra (Sildenafil Citrate)
• 5.3 Cialis (Tadalafil)
• 5.4 Levitra/Staxyn (Vardenafil)
• 5.5 Stendra/Spedra (Avanafil)
• 5.6 Zydena (Udenafil)
• 5.7 Other drugs

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Parenteral
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Bayer
• 9.2 Eli Lilly and Company
• 9.3 Endo
• 9.4 Futura Medical
• 9.5 Hims & Hers Health
• 9.6 Lupin
• 9.7 Meda Pharmaceuticals
• 9.8 Petros Pharmaceuticals
• 9.9 Pfizer
• 9.10 Sandoz
• 9.11 Simple Pharma
• 9.12 Sun Pharmaceutical Industries
• 9.13 Teva Pharmaceutical Industries
• 9.14 Zydus Lifesciences